ACT (2011) — Trial Summary

ACT (2011): The Acetylcysteine (ACT) trial evaluated whether oral acetylcysteine prevents contrast-induced acute kidney injury and associated adverse outcomes in high-risk patients undergoing coronary and peripheral angiography.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.